Skip to main content
. Author manuscript; available in PMC: 2020 Aug 15.
Published in final edited form as: Clin Cancer Res. 2019 Sep 26;26(4):804–811. doi: 10.1158/1078-0432.CCR-19-1223

Table 3.

High-grade adverse events

N %
Patients with at least one: Arm 16 51.6
Grade 3+ Adverse Event 1
2 3 20.0
2X 3 33.3
Grade 4+ Adverse Event 1 1 3.2
2 2 13.3
Grade 3+ Hem Adverse Event 2 2 13.3
Grade 4+ Hem Adverse Event 2 2 13.3
Grade 3+ Non-Hem Adverse Event 1 16 51.6
2 1 6.7
2X 3 33.3
Grade 4+ Non-Hem Adverse Event 1 1 3.2